Condition: Hepatitis C · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection (acute or chronic) with or without HIV and to evaluate safety for their infants through 10 weeks postpartum.
This description comes directly from the study's public registry record.
IMPAACT ClinicalTrials.gov Coordinator · impaact.ctgov@fstrf.org
Katie McCarthy · 919-321-3326 · kmccarthy@fhi360.org
Always discuss trial participation with your own doctor first.
| USC LA | Los Angeles, California, United States | Recruiting |
| David Geffen School of Medicine at UCLA | Los Angeles, California, United States | Not Yet Recruiting |
| University of Colorado Denver | Aurora, Colorado, United States | Recruiting |
| Univ. of Florida Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Johns Hopkins University Baltimore | Baltimore, Maryland, United States | Recruiting |
| SUNY Stony Brook | Stony Brook, New York, United States | Recruiting |
| Bronx-Lebanon Hospital Center | The Bronx, New York, United States | Recruiting |
| Jacobi Medical Center | The Bronx, New York, United States | Not Yet Recruiting |
| Baylor College of Medicine//Texas Children's Hospital | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07040319